Top news of the week: 15.02.2023.
EYLEA® (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA
ROP is a leading cause of childhood blindness worldwide EYLEA now approved to treat five retinal conditions caused by ocular angiogenesis TARRYTOWN, N.Y. , Feb. 08, 2023 (GLOBE NEWSWIRE) -- ...
Pfizer, Novartis, Merck Executives Say They Are Hunting for Deals Again
Big drugmakers are looking for new products because lower-priced competitors are coming that could take away nearly a quarter of sales.
U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...
Another IL-12 Candidate Bites the Dust as AstraZeneca Shifts Focus
AstraZeneca announced it is making significant cuts from its pipeline in an attempt to realign its priorities and recover from waning COVID-19 drug sales.
Enabling High-throughput Biology with New Technologies for Synthetic Construct Sequencing
Date: March 07, 2023 Time: 9:00am (PST), 12:00pm (EST), 6:00pm (CET) The ability to synthesize and sequence vast numbers of DNA constructs is a cornerstone of modern high-throughput biologic
KGK Science, Nova Mentis Cleared for Psilocybin Clinical Trial to Treat Fragile X Syndrome
KGK Science will begin with its partner Nova Mentis Life Science a clinical trial assessing psilocybin as a therapy for fragile X syndrome.
Algorithm Profiles Metabolic Gene Clusters in the Human Gut Microbiome
A new software identifies primary metabolic gene clusters in specific microbial taxonomic groups that are important in host–microbiome interactions.
Talking about Alzheimer’s disease: current drugs, clinical trials, and the pipeline
In this podcast about Alzheimer's disease, learn about current drugs, the latest clinical trials, the pipeline and future treatments!